[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644510":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":72,"collaborators":25,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":25,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":25,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":25,"overallStatus":93,"whyStopped":25,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HRS9531 Tablet Group","EXPERIMENTAL","HRS9531 tablet.",[13],"Drug: HRS9531 Tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"HRS9531 Tablet Placebo Group","PLACEBO_COMPARATOR","HRS9531 tablet placebo.",[19],"Drug: HRS9531 Tablet Placebo",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","HRS9531 Tablet",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"HRS9531 Tablet Placebo",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Qiannan Zhou, M.M","CONTACT","+86-0518-82342973","qiannan.zhou@hengrui.com",[36,56],{"facility":37,"status":25,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Henan Provincial People's Hospital","Zhengzhou","Henan","450003","China","CN",{"type":44,"coordinates":45},"Point",[46,47],113.64861,34.75778,{"lat":47,"lon":46},[50,54],{"name":51,"role":32,"phone":52,"phoneExt":25,"email":53},"Huijuan Yuan","+86-0371-65580371","hjyuan@zzu.edu.cn",{"name":51,"role":55,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"facility":57,"status":25,"city":58,"state":59,"zip":60,"country":41,"countryCode":42,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Nanjing Drum Tower hospital","Nanjing","Jiangsu","210008",{"type":44,"coordinates":62},[63,64],118.77778,32.06167,{"lat":64,"lon":63},[67,71],{"name":68,"role":32,"phone":69,"phoneExt":25,"email":70},"Yan Bi","+86-025-83106666","biyan@nju.edu.cn",{"name":68,"role":55,"phone":25,"phoneExt":25,"email":25},{"type":73,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100644510","phase-3-a-clinical-study-to-evaluate-the-efficacy-and-safety-of-hrs9531-tablets-in-overweight-or-obese-subjects-100644510",false,"NCT07670884","A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects","Inclusion Criteria:\n\n1. Male or female subjects, 18-75 years of age at the time of signing informed consent;\n2. At screening visit, BMI ≥ 28 kg\u002Fm2 or ≥ 24 kg\u002Fm2 with at least one weight-related comorbidity;\n3. Diet and exercise control for at least 3 months before screening visit, and the weight change does not exceed 5% within the last 3 months;\n4. Able and willing to provide a written informed consent.\n\nExclusion Criteria:\n\n1. Presence of clinically significant lab or ECG results that may affect the evaluation of the efficacy or safety of the study drug at screening visit;\n2. Uncontrollable severe hypertension;\n3. PHQ-9 score ≥ 15;\n4. Medical history or illness that affects body weight;\n5. History of diabetes;\n6. Acute or chronic hepatitis;\n7. History of severe cardiovascular and cerebrovascular diseases within 6 months prior to screening;\n8. Any organ-system malignancies developed within 5 years;\n9. Acute infection, acute trauma, or medium to large surgery within 30 days prior to screening;\n10. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness, mentally incapacitated or speech-impaired;\n11. Use of any medication or treatment that may have caused significant weight change within 90 days;\n12. History of bariatric surgery;\n13. Known or suspected hypersensitivity to trial product(s) or related products;\n14. History of alcohol and\u002For substance abuse or drug abuse;\n15. History of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening;\n16. Surgery is planned during the trial;\n17. The investigators determined that other conditions were inappropriate for participation in this clinical trial.","ALL","18 Years","75 Years",{"count":85,"type":86},425,"ESTIMATED","INTERVENTIONAL",[89],"PHASE3","This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.",[92],"Chronic Management of Body Weight","NOT_YET_RECRUITING","2026-06-22",{"date":96,"type":97},"2026-06-26","ACTUAL",{"date":99,"type":86},"2026-07",{"date":101,"type":86},"2027-08",{"name":5,"class":6},2]